Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones certainly are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a session of antib

Home | Submit Articles | Login

Number Times Read : 2 Word Count: 770

Stats
Total Articles: 393,563 Total Authors: 41,743 Total Downloads: 2,125,033 Newest Member Mohamed Bozeman

Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones certainly are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a session of antib

Category Rss Feed - http://www.ezarticlesdb.com/rss.php?rss=88

By : Sharifi Rodregez zero times read

Submitted 2012-02-13 21:14:16

The fluoroquinolones really are a breed of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of many group is nalidixic acid, found in 1962 by Lescher and colleagues. The earliest fluoroquinolones were often since they were the sole orally administered agents an alternative for handling serious infections as a result of gram-negative organisms, including Pseudomonas species.

The newer fluoroquinolones possess a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones posses important part in the treatment of community-acquired pneumonia and intra-abdominal infections.

Fluoroquinolones disadvantages:

Tendonitis or tendon rupture
Multiple drug interactions
Not used in kids
Newer quinolones produce additional toxicities towards the heart that were not found in the older brokers
Fluoroquinolones advantages:
Simplicity of administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety

Classification of Fluoroquinolones
As a thoughtful group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal discount in activity against gram-negative bacteria. Their expanded gram-positive activity is extremely important this is because includes significant activity against Streptococcus pneumoniae.

First Generation. The first-generation agents include cinoxacin and nalidixic acid, knowing the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were put to use primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing when compared to the newer quinolones, and are also more susceptible to the development of bacterial resistance.

Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. When compared to first-generation quinolones, these drugs have broader clinical applications within the remedy for complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections.

Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin would be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are classified as the preferred second-generation quinolones because of the availability in oral and intravenous formulations and the broad range of FDA-labeled indications.

Third Generation. The third-generation fluoroquinolones are separated right into a third class because of the expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for instance Mycoplasma pneumoniae and Chlamydia pneumoniae. Although the third-generation agents retain broad gram-negative coverage, they may be less active than ciprofloxacin against Pseudomonas species.

Owing to their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful inside the remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.

Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative activity of the third-generation drugs. Additionally retain activity against Pseudomonas species corresponding to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).

Due to bother about hepatotoxicity, trovafloxacin therapy should be available to life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), as well as the drug is necessary for no more than 14 days.

Side effects

The fluoroquinolones to be a class some times well tolerated. Most negative effects are mild in severity, self-limited, and barely end in treatment discontinuation. However, they can have serious adverse reactions.

Fluoroquinolones are approved for use only in people older than 18. They could affect the increase of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating which these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy will not be recommended unless the benefits justify the potential risks into the fetus. These agents are also excreted in breast milk and may be bypassed during breast-feeding whether possible.

Gastrointestinal effects. A typical side effects familiar with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur approx 1 to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness seem to have been reported for all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, seem to have been reported in patients receiving trovafloxacin. Seizures may develop within 3 - 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should really be avoided in patients that has a tradition of convulsion, cerebral trauma, or anoxia. No seizures have already been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. In the older non-fluorinated quinolones neurotoxic symptoms for example dizziness occurred in about 50% of the patients.
Phototoxicity. Knowledge of ultraviolet A rays from directly or indirectly sunlight should be avoided during treatment and several other days (5 days with sparfloxacin) as the use of the drug. The degree of phototoxic potential of fluoroquinolones is just as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Bother about the creation of musculoskeletal effects, evident in animal studies, has led into the contraindication of fluoroquinolones for routine use in children whereas in the women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have already been reported provided nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant utilization of corticosteroids.
Hepatoxicity. Trovafloxacin use has long been linked to rare liver damage, which prompted the withdrawal of a typical oral preparations from the U.S. market. However, the IV preparation continues to be readily available for remedy for infections so serious that the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones are actually found to supply additional toxicities towards the heart that were not found together with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin could have essentially the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have already been mild.
Hypersensitivity. Hypersensitivity reactions occur hardly during quinolone therapy and can be mild to moderate in severity, and typically resolve after treatment is stopped.

Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones possess a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones contain an important part in treating community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones diverge from 3 -20 hours, granting maybe once or twice daily dosing.

Author Resource:- The fluoroquinolones are an order of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of many group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The very first fluoroquinolones were usually mainly because they were the only orally administered agents readily available for managing serious infections as a result of gram-negative organisms, including Pseudomonas species. The newer fluoroquinolones possess a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones contain an important role in managing community-acquired pneumonia and intra-abdominal infections. Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in children Newer quinolones produce additional toxicities to the heart have been not found with the older brokers Fluoroquinolones advantages: Ease of administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety Classification of Fluoroquinolones As a group, the fluoroquinolones have excellent in vitro activity against a large choice of both gram-positive and gram-negative bacteria. Modern-day fluoroquinolones have enhanced activity against gram-positive bacteria with only a small lowering of activity against gram-negative bacteria. Their expanded gram-positive activity is especially important as it includes significant activity against Streptococcus pneumoniae. First Generation. The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were put to use primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they're more susceptible to the development of bacterial resistance. Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, and also some gram-positive and atypical pathogen coverage. When compared to first-generation quinolones, these drugs have broader clinical applications in the treatment of complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections. Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin would be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin will be the hottest second-generation quinolones owing to their availability in oral and intravenous formulations as well as their broad set of FDA-labeled indications. Third Generation. The third-generation fluoroquinolones are separated into a third class owing to their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens similar to Mycoplasma pneumoniae and Chlamydia pneumoniae. Despite the fact that the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species. Due to expanded antimicrobial spectrum, third-generation fluoroquinolones are helpful inside the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which you ll find are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative workings of the third-generation drugs. In addition they retain activity against Pseudomonas species similar to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan). Due to worry about hepatotoxicity, trovafloxacin therapy should be kept for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug is critical for no longer than 14 days. Unwanted effects The fluoroquinolones as a class quite some time well tolerated. Most adverse effects are mild in severity, self-limited, and infrequently set off treatment discontinuation. However, they can have serious adverse reactions. Fluoroquinolones are approved for use only in people older than 18. They can affect the expansion of bones, teeth, and cartilage within a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during your pregnancy is not really recommended unless the benefits justify the possible risks to your fetus. These agents can be excreted in breast milk and will be avoided during breast-feeding whether possible. Gastrointestinal effects. The commonest side effects experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in one to 5% of patients. CNS effects. Headache, dizziness, and drowsiness are actually reported for all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, are actually reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones ought to be avoided in patients by using a history of convulsion, cerebral trauma, or anoxia. No seizures seem to have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. Together with the older non-fluorinated quinolones neurotoxic symptoms for instance dizziness happened about 50% of the patients. Phototoxicity. Knowledge of ultraviolet A rays from directly or indirectly sunlight should really be avoided during treatment and several days (5 days with sparfloxacin) after the utilization of prescription. The degree of phototoxic potential of fluoroquinolones is often as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and then in women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 1 week of discontinuation of therapy, spontaneous ruptures have already been reported provided that nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use has long been connected with rare liver damage, which prompted the withdrawal of your oral preparations out of your U.S. market. However, the IV preparation continues to be an alternative for remedy for infections so serious the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to supply additional toxicities towards the heart that were not found with the older compounds. Evidence means that sparfloxacin and grepafloxacin can have by far the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have already been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has long been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur hardly during quinolone therapy and tend to be mild to moderate in severity, and typically resolve after treatment is stopped. Conditions treated with Fluoroquinolones: indications and uses The newer fluoroquinolones have got a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones have an important aspect in treating community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of a typical fluoroquinolones vary from 3 -20 hours, allowing for a few times daily dosing.

Article From EzArticlesDb.com

Related Articles

HTML Ready Article. Click on the "Copy" button to copy into your clipboard.

<!DOCTYPE HTML PUBLIC '-//W3C//DTD HTML 4.01 Transitional//EN' 'http://www.w3.org/TR/html4/loose.dtd'><html><head><title>EzArticlesDb.com | Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones certainly are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a session of antib</title></head><body><h3>Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones certainly are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a session of antib</h3> By: Sharifi Rodregez The fluoroquinolones really are a breed of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of many group is nalidixic acid, found in 1962 by Lescher and colleagues. The earliest fluoroquinolones were often since they were the sole orally administered agents an alternative for handling serious infections as a result of gram-negative organisms, including Pseudomonas species. The newer fluoroquinolones possess a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones posses important part in the treatment of community-acquired pneumonia and intra-abdominal infections. Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in kids Newer quinolones produce additional toxicities towards the heart that were not found in the older brokers Fluoroquinolones advantages: Simplicity of administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety Classification of Fluoroquinolones As a thoughtful group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal discount in activity against gram-negative bacteria. Their expanded gram-positive activity is extremely important this is because includes significant activity against Streptococcus pneumoniae. First Generation. The first-generation agents include cinoxacin and nalidixic acid, knowing the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were put to use primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing when compared to the newer quinolones, and are also more susceptible to the development of bacterial resistance. Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. When compared to first-generation quinolones, these drugs have broader clinical applications within the remedy for complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections. Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin would be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are classified as the preferred second-generation quinolones because of the availability in oral and intravenous formulations and the broad range of FDA-labeled indications. Third Generation. The third-generation fluoroquinolones are separated right into a third class because of the expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for instance Mycoplasma pneumoniae and Chlamydia pneumoniae. Although the third-generation agents retain broad gram-negative coverage, they may be less active than ciprofloxacin against Pseudomonas species. Owing to their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful inside the remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative activity of the third-generation drugs. Additionally retain activity against Pseudomonas species corresponding to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan). Due to bother about hepatotoxicity, trovafloxacin therapy should be available to life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), as well as the drug is necessary for no more than 14 days. Side effects The fluoroquinolones to be a class some times well tolerated. Most negative effects are mild in severity, self-limited, and barely end in treatment discontinuation. However, they can have serious adverse reactions. Fluoroquinolones are approved for use only in people older than 18. They could affect the increase of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating which these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy will not be recommended unless the benefits justify the potential risks into the fetus. These agents are also excreted in breast milk and may be bypassed during breast-feeding whether possible. Gastrointestinal effects. A typical side effects familiar with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur approx 1 to 5% of patients. CNS effects. Headache, dizziness, and drowsiness seem to have been reported for all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, seem to have been reported in patients receiving trovafloxacin. Seizures may develop within 3 - 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should really be avoided in patients that has a tradition of convulsion, cerebral trauma, or anoxia. No seizures have already been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. In the older non-fluorinated quinolones neurotoxic symptoms for example dizziness occurred in about 50% of the patients. Phototoxicity. Knowledge of ultraviolet A rays from directly or indirectly sunlight should be avoided during treatment and several other days (5 days with sparfloxacin) as the use of the drug. The degree of phototoxic potential of fluoroquinolones is just as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Bother about the creation of musculoskeletal effects, evident in animal studies, has led into the contraindication of fluoroquinolones for routine use in children whereas in the women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have already been reported provided nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant utilization of corticosteroids. Hepatoxicity. Trovafloxacin use has long been linked to rare liver damage, which prompted the withdrawal of a typical oral preparations from the U.S. market. However, the IV preparation continues to be readily available for remedy for infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones are actually found to supply additional toxicities towards the heart that were not found together with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin could have essentially the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have already been mild. Hypersensitivity. Hypersensitivity reactions occur hardly during quinolone therapy and can be mild to moderate in severity, and typically resolve after treatment is stopped. Conditions treated with Fluoroquinolones: indications and uses The newer fluoroquinolones possess a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones contain an important part in treating community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones diverge from 3 -20 hours, granting maybe once or twice daily dosing. Author Resource:-> The fluoroquinolones are an order of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of many group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The very first fluoroquinolones were usually mainly because they were the only orally administered agents readily available for managing serious infections as a result of gram-negative organisms, including Pseudomonas species. The newer fluoroquinolones possess a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones contain an important role in managing community-acquired pneumonia and intra-abdominal infections. Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in children Newer quinolones produce additional toxicities to the heart have been not found with the older brokers Fluoroquinolones advantages: Ease of administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety Classification of Fluoroquinolones As a group, the fluoroquinolones have excellent in vitro activity against a large choice of both gram-positive and gram-negative bacteria. Modern-day fluoroquinolones have enhanced activity against gram-positive bacteria with only a small lowering of activity against gram-negative bacteria. Their expanded gram-positive activity is especially important as it includes significant activity against Streptococcus pneumoniae. First Generation. The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were put to use primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they're more susceptible to the development of bacterial resistance. Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, and also some gram-positive and atypical pathogen coverage. When compared to first-generation quinolones, these drugs have broader clinical applications in the treatment of complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections. Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin would be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin will be the hottest second-generation quinolones owing to their availability in oral and intravenous formulations as well as their broad set of FDA-labeled indications. Third Generation. The third-generation fluoroquinolones are separated into a third class owing to their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens similar to Mycoplasma pneumoniae and Chlamydia pneumoniae. Despite the fact that the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species. Due to expanded antimicrobial spectrum, third-generation fluoroquinolones are helpful inside the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which you ll find are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative workings of the third-generation drugs. In addition they retain activity against Pseudomonas species similar to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan). Due to worry about hepatotoxicity, trovafloxacin therapy should be kept for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug is critical for no longer than 14 days. Unwanted effects The fluoroquinolones as a class quite some time well tolerated. Most adverse effects are mild in severity, self-limited, and infrequently set off treatment discontinuation. However, they can have serious adverse reactions. Fluoroquinolones are approved for use only in people older than 18. They can affect the expansion of bones, teeth, and cartilage within a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during your pregnancy is not really recommended unless the benefits justify the possible risks to your fetus. These agents can be excreted in breast milk and will be avoided during breast-feeding whether possible. Gastrointestinal effects. The commonest side effects experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in one to 5% of patients. CNS effects. Headache, dizziness, and drowsiness are actually reported for all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, are actually reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones ought to be avoided in patients by using a history of convulsion, cerebral trauma, or anoxia. No seizures seem to have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. Together with the older non-fluorinated quinolones neurotoxic symptoms for instance dizziness happened about 50% of the patients. Phototoxicity. Knowledge of ultraviolet A rays from directly or indirectly sunlight should really be avoided during treatment and several days (5 days with sparfloxacin) after the utilization of prescription. The degree of phototoxic potential of fluoroquinolones is often as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and then in women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 1 week of discontinuation of therapy, spontaneous ruptures have already been reported provided that nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use has long been connected with rare liver damage, which prompted the withdrawal of your oral preparations out of your U.S. market. However, the IV preparation continues to be an alternative for remedy for infections so serious the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to supply additional toxicities towards the heart that were not found with the older compounds. Evidence means that sparfloxacin and grepafloxacin can have by far the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have already been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has long been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur hardly during quinolone therapy and tend to be mild to moderate in severity, and typically resolve after treatment is stopped. Conditions treated with Fluoroquinolones: indications and uses The newer fluoroquinolones have got a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones have an important aspect in treating community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of a typical fluoroquinolones vary from 3 -20 hours, allowing for a few times daily dosing. Article From <a href='http://www.ezarticlesdb.com/'>EzArticlesDb.com</a> </body></html>

Firefox users please select/copy/paste as usual

Rate This Article
Vote to see the results!

Do you like this article?

New Members
	Sign up
	learn more


Nav Menu
	Home
	Login
	Submit Articles
	Submission Guidelines
	Top Articles
	Link Directory
	About Us
	Contact Us
	Privacy Policy
	RSS Feeds

Actions

Print This Article

Add To Favorites

Privacy Policy \| Contact us
Quality Original Free Articles © 2010 - 2012 EzArticlesDb.com - All Rights Reserved.